Eikon Therapeutics, Inc.

Filing Date

Feb 4, 2026

Transaction Date

Feb 4, 2026

Accession Number

0001193125-26-038158

Form Type

3

Footnotes

1. (F1)The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
2. (F2)These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. Peter Hebert and the Reporting Person (the "Individual Lux Managers") are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
3. (F3)The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
4. (F4)These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. The Individual Lux Managers are the individual managing members of LCIP II, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
5. (F5)The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
6. (F6)These shares are held by Lux Total Opportunities, L.P., ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP, and as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. The Reporting Person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
7. (F7)The Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
8. (F8)The Series C Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
9. (F9)The Series C-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
10. (F10)The Series D Preferred Stock is convertible into Common Stock on a 1-for 7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series D Preferred Stock will be converted into shares of Common Stock of the Issuer.